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Interleukin 2 (IL-2), 1 formerly called T cell growth factor, provides a necessary 
signal for the transition  of activated T  cells from the G1 to the S phase of the 
cell cycle (1,  2).  The  mechanism  of action of the factor involves binding  to a 
high-affinity receptor on the surface of responsive cells (3, 4). Based on a number 
of criteria,  the  murine  monoclonal  antibody  anti-Tac,  originally  prepared  by 
Uchiyama and co-workers (5), recognizes the human IL-2 receptor. The antibody 
was capable of blocking high-affinity IL-2 binding to activated cells (6, 7) and all 
of the  T  cell  responses  attributed  to  interaction  of such  cells  with  IL-2  (8). 
Furthermore,  a covalent complex of IL-2 and Tac protein was isolated from IL- 
2-treated  cells  that  had  been  subjected to  chemical  cross-linking  (9). Finally, 
affinity supports coupled with the antibody and with IL-2 bound the same 55,000 
mol wt glycoprotein from a  mixture of detergent-solubilized cellular molecules 
(7).  The antibody-coupled support was capable of removing all cellular proteins 
reactive  with  the  IL-2-coupled  support,  and  the  IL-2-coupled  support  was 
capable of removing all antibody-reactive molecules. Thus, the number of IL-2 
receptors appeared equal to the number of Tac proteins. In contrast to the latter 
finding, quantitative binding assays with radiolabeled IL-2 and anti-Tac indicated 
that activated T  cells had  10-20 times more binding sites for the antibody than 
high-affinity sites for IL-2(10). Resolution of this dilemma is essential if the anti- 
Tac  reagent  is  to be used  to  monitor  expression  of the  IL-2  receptor  in  the 
absence of direct binding data. 
As earlier suggested (7), one potential explanation for the quantitative differ- 
ence between the two binding assays is that a  large portion of the Tac proteins 
possess a  low affinity  for  IL-2.  Such  molecules  would  bind  to  IL-2-coupled 
supports but would not have appeared in the original radiolabeled IL-2 binding 
assays (3), which were conducted at very low IL-2 concentrations.  In this paper, 
we describe a binding phenomenon for IL-2 on activated T  cells and certain  B 
cells that  has  an  association  constant  >5,000  times  lower than  that  originally 
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described (3). Moreover, the number of such binding sites was many times the 
number  of high-affinity  sites.  As  with  the  high-affinity  interaction,  the  low- 
affinity binding of radiolabeled IL-2 was blocked by addition of excess unlabeled 
factor and substantially blocked by the addition of the anti-Tac antibody. Con- 
sidering  the  accuracy  of  the  methodology,  the  levels  of  total  binding  sites 
measured using radiolabeled IL-2 and anti-Tac were quite similar, thus support- 
ing the notion that the two assays detect coincident sets of molecules. 
Materials and Methods 
Cell  Cultures.  The three  murine,  IL-2-dependent cytotoxic T  cell lines (CTLL-2, 
subclone 15H [ 11 ] and CTL, a gift from Dr. T. Malek, National Institutes of Health) and 
helper T  cell lines (HT-2, a gift from Dr. T. Malek) were maintained in Iscove's modified 
Dulbecco's modified Eagle medium (Iscove's DME; Grand Island Biological Co., Grand 
Island,  NY)  supplemented  with  15%  heat-inactivated fetal  bovine serum  (FBS,  M.A. 
Bioproducts, WalkersviUe,  MD),  100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM t.- 
glutamine, 2.5 ×  10  -5 M  2-mercaptoethanol, and  1.0  U/ml purified JURKAT-derived 
IL-2. All human and primate cell lines were maintained in RPMI  1640 medium (Grand 
Island Biological) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 
#g/rot  streptomycin, and  2  mM  L-glutamine.  All  cells  were cultured  in  a  humidified 
atmosphere of 5% CO2 in air at 37°C. The 1C9 cell line was obtained by transformation 
of Tac-positive, normal human B cells with Epstein-Barr virus and was a generous gift 
from Dr. T. Waldmann,  National Institutes of Health. A sample of hairy cell leukemia 
(HCL) was a kind gift from Dr. S. Korsmeyer. T  lymphocytes were first removed from 
this sample by sheep erythrocyte rosetting before receptor binding analysis.  HSB~ cells (1 
x  106 cells/ml) were stimulated  with  50 ng/ml phorbol-12-myristate-13-acetate (PMA; 
Consolidated Midlands Corp., Brewster, NY) for 20 h before receptor analysis. 
Human phytohemagglutinin(PHA)-activated lymphoblasts were prepared by culturing 
peripheral blood mononuclear cells isolated on Ficoll-Hypaque with 1.5 ~g/ml PHA (HA- 
16; Wellcome Reagents, England) in supplemented RPMI  1640 medium for 72 h. The 
proportion of blast cells was enriched to >95% by discontinuous Percoll (Pharmacia, Inc., 
Uppsala, Sweden) gradient centrifugation (12).  For short-term culture of PHA-lympho- 
blasts,  the 72-h blast cells were washed and resuspended at  1 ×  105 cells/ml in supple- 
mented RPMI 1640 with 1 U/ml IL-2. Every 48 h, the cells were pelleted and resuspended 
in  fresh medium containing IL-2. At 9 d  after the original lectin stimulation, the cells 
were restimulated with 1.0 #g/ml PHA in the presence of IL-2. Receptor expression was 
measured after 16 h. 
Interleukin 2.  Biosynthetically radiolabeled and unlabeled IL-2 were prepared from 
the cell supernatant of a high-producing subclone of the JURKAT cell line (16.8.9.15.32) 
after induction of the cells with PHA and PMA (13). The cells were suspended at 4  x 
106/ml  in serum-free DME for the preparation of unlabeled IL-2 and in leucine, lysine- 
free DME (Grand Island Biological Co.), to which was added 40 #M unlabeled leucine 
and 65 #M unlabeled lysine, for the radiolabeled preparations. To the latter cultures were 
added 0.1-0.5 mCi/ml [aH]leucine (50 Ci/mmol; ICN, Irvine, CA) and 0.1-0.5 mCi/ml 
[3H]lysine (45 Ci/mmol; ICN). IL-2 secretion was induced by inclusion of 1.5 #g/ml PHA 
and 50 ng/ml PMA. The cell supernatant was harvested after 16 h at 37°C. Bovine serum 
albumin  (BSA;  Sigma  Chemical  Co.,  St.  Louis,  MO)  at  1  mg/ml  was  added  to  the 
radiolabeled preparations as a carrier. 
IL-2 was purified from theJURKAT cell supernatant using an immunoaffinity column 
coupled with a murine monoclonai antibody (46C8-A2) specific for the N-acetyl galactos- 
amine derivative of human I L-2 (14, 15). This form of I L-2 represents -60 % of the factor 
released by stimulated J URKAT cells (16). Separate experiments have demonstrated that 
the affinity of IL-2 for its cellular receptor is not affected by the extent of glycosylation 
of the factor (3,  15). Bound IL-2 was recovered in >95% yield by elution of the affinity 
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by two-dimensional gel electrophoresis (16),  reverse-phase HPLC (unpublished observa- 
tion), and N-terminal sequence analysis  (16).  The material was free of PHA and PMA, 
based on the gel electrophoretic data and [sH]PMA (New England Nuclear, Boston, iMA  ) 
tracer analysis  (16).  The radiolabeled IL-2 was eluted from the affinity column in  1.5% 
HOAc with  1 mg/ml  BSA and equilibrated with  RPMI  1640,  25 mM Hepes, pH  7.2 
(Grand Island Biological Co.) on a  YM-5  membrane (Amicon Corp.,  Lexington, MA). 
The specific radioactivity of [SH]ieu,lys IL-2, in terms of dpm SH per picomole IL-2, was 
estimated by measuring the bioactivity of the preparation in the T cell proliferation assay 
(see next section) and converting this value to the weight of IL-2 using the previously 
determined specific activity of the factor (3 I0,000 units of bioactivity per milligram of 
IL-2 protein; reference 16) and its molecular weight (15,500 pg/pmol). 
lnterleukin 2 Bioassay.  IL-2 bioactivity was determined by the concentration-dependent 
stimulation  of proliferation, as  indicated by  [3H]thymidine (TdR) incorporation, of a 
cloned, I L-2-dependent murine T  cell line (CTLL-2, subclone 15H) (17). Serial twofold 
dilutions of the samples and a  standard  IL-2 preparation  were incubated with  4,000 
CTLL cells (200 #1 total volume) for a period of 16-18 h. At that time, the cultures were 
pulsed with 50 ~l of [SH]TdR, 10 ~Ci/ml (New England Nuclear). After 4 h, the cultures 
were harvested on glass fiber paper using a Titertek Cell Harvester (Flow Laboratories, 
Rockville, MD). The dilutions yielding half-maximal [SH]TdR incorporation were deter- 
mined by probit analysis  (17) and the dilution of the sample was divided by that of the 
standard  to  yield  the  IL-2  concentration  in  units  per  milliliter.  The  standard  IL-2 
preparation was arbitrarily assigned a value of 1 U/ml and induced 50% of the maximum 
[SH]TdR incorporation at a final dilution of 1:20 to 1:40 (the final dilution after addition 
of 100 ~1 of the CTLL suspension) (13). As used here, 1 U of bioactivity was equivalent 
to ~41.5 IL-2 Reference Reagent "units" as defined by the Biological Response Modifiers 
Program of the National Cancer Institute. 
Anti-Tac Monoclonal Antibody.  The anti-Tac antibody (5) was purified from the ascites 
fluid of hybridoma-inoculated BALB/c mice using protein  A-Sepharose (Sigma).  The 
antibody  was  radiolabeled  by  reductive  methylation  with  formaldehyde and  sodium 
[SH]borohydride (New England  Nuclear) (9).  The specific radioactivity was  calculated 
using an  average of the  protein  content as determined by the  Lowry assay  (18) and 
quantitative amino acid compositional analysis. 
Radiolabeted IL-2 and Anti-Tac Binding Assays.  Before determining the level of binding, 
all cell types were incubated twice for 1 h at 37°C in 50 ml RPMI  1640 with extensive 
washing between and after the incubations in order to remove endogenous IL-2. Previous 
studies  (3,  19)  have  indicated  that  receptor-bound  IL-2  will  either  dissociate  or  be 
internalized during this time period. In some cases, the washed cells were also incubated 
for 20 s in  10 mM sodium citrate, 0.14 M NaCI,  pH 4.0 followed by centrifugation at 
9,000 g for 15 s in a Microfuge 12 (Beckman Instruments, Palo Alto, CA), a procedure 
shown  to  remove  intact  cell  surface-bound  IL-2  (19).  After  washing,  the  cells  were 
resuspended in RPMI  1640, 25 mM Hepes, pH 7.3, containing 10 mg/ml BSA (RPMI- 
BSA). Identical binding results were obtained using RPMI 1640 with 10% fetal calf serum 
in place of the BSA. 
To determine the level of binding, serial dilutions of [SH]leu,lys IL-2 and [!H]anti-Tac 
IgG were incubated at 37°C with 0.3-2 x  10  ~ cells in a total volume of I00 tA RPMI- 
BSA using  1.5-ml  Eppendorf micro test tubes (Brinkman Instruments,  Westbury, NY). 
For the anti-Tac binding assay, a  control murine myeioma IgG2a antibody, designated 
UPC-10 (Litton Bionedcs Inc., Kensington, MD), was included at 200 ~tg/ml to minimize 
potential interactions of the [SH]anti-Tac with Fc receptors. The tubes were mechanically 
rotated about their longest axis (horizontal position) at 20 rpm in a 37°C water bath for 
20-30 min. In separate experiments (unpublished observations), it was determined that 
this period of incubation was sufficient to allow maximum high (20 rain) and low-affinity 
(30 min) binding to occur. After incubation with the radiolabeled probe, the cells were 
washed two to four times, depending upon the amount of radiolabel added, with 1 ml ice- 
cold RPMI-BSA. The supernatant from the first wash was counted by liquid scintillation 
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in  100  #!  RPMI-BSA and centrifuged (9,000 g  for 90 s) through a  200  #l  layer of a 
mixture of 84% silicone oil (550 fluid; Contour Chemical Co., North Reading, MA) and 
16% paraffin oil (Fisher Scientific Co., Philadelphia, PA) to remove the small amount of 
residual  unbound  radioactivity. The  tips  of the  tubes  (400-#1 polyethylene; Bio-Rad 
Laboratories, Richmond, CA) containing the cell pellet were cut off and placed in 20-ml 
glass scintillation vials. The cells were expelled from the tips using 200 #1 phosphate- 
buffered saline (PBS) and solubilized by the addition of 200 #1 1% SDS, followed by 10 
ml Liquiscint (National Diagnostics,  Somerville, N  J). The radioactivity was counted by 
liquid scintillation on a Tri-Carb 4640 (Packard Instrument Co., Downers Grove, IL). 
The results  were converted  to  dpm  before applying graphical analysis.  The average 
counting efficiency for the bound fraction was 39% and, for the unbound fraction, 32%. 
Results 
Purity of Radiolabeled  Probes.  The  radiolabeled  IL-2 and anti-Tac reagents 
were purified by affinity chromatography on anti-IL-2 monoclonal antibody and 
protein A-coupled columns, respectively. The [3H]IL-2 was prepared at several 
different levels of specific radioactivity in order to measure binding over a  wide 
range of concentrations.  SDS-polyacrylamide gel  electrophoretic  (SDS-PAGE) 
analysis  of the  various  radiolabeled  probes  indicated  that  each  of the  IL-2 
preparations consisted of a single labeled component of 15,500 tool wt and that 
the  [3H]anti-Tac  preparation :contained  only  the  50,000  and  25,000  mol  wt 
bands expected of heavy and light IgG chains (Fig.  1). 
Extension  of the  [~H]IL-2  Binding  Assay  to  High  IL-2  Concentrations.  The 
radiolabeled  IL-2  binding  assays originally described  by  Robb  et al.  (3)  used 
IL-2 concentrations between  1 and  200  pM.  At these  IL-2  levels, the authors 
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FIGURE  1.  SDS-PAGE  analysis (12% acrylamide, samples treated with 2-mercaptoethanol, 
$  5  reference 16) of three preparations of [ H]IL-2 with specific  radioactivities  of 3.82 × 10  dpm/ 
pmol (lane a), 2.42 × 105 dpm/pmol (lane b), and 3.09 × 104 dpm/pmol (lane c) and of [3HI 
anti-Tac antibody (8.33 ×  104 dpm/pmol, lane d). About 20,000 dpm of each of the IL-2 
radiolabeled probes and  10,000 dpm of the anti-Tac probe were applied to the gel. The 
radioactivity  was visualized by fluorography (36). 1130  LOW  AND  HIGH  AFFINITY  IL-2  RECEPTORS 
demonstrated a saturable binding phenomenon with a dissociation constant (Kd) 
of 5-6 pM for activated human T  cells and 20 pM for activated murine T  cells. 
The number of binding sites detected on  the human cells,  however, was  far 
below that estimated using the anti-Tac monoclonal antibody (6, 8, 10). A similar 
discrepancy was  suspected  for  the  murine  T  cells based  on  the  intensity  of 
fluorescence staining with a rat monoclonal antibody (20) specific for the murine 
IL-2 receptor (unpublished observation)• Since it was possible that  IL-2  might 
also interact with a  distinct set of sites with a  markedly lower affinity (7),  the 
binding curve analysis was extended up to IL-2 concentrations 1,000-fold higher 
than originally used. The results of such a binding experiment, as shown in Fig. 
2, confirmed that high-affinity saturable binding occurred at IL-2 concentrations 
<1  nM.  At  IL-2  concentrations above  this  level,  however,  additional  factor 
binding was detected.  In this experiment, the Kd of the binding at high IL-2 
concentrations for the human T  cell leukemia/lymphoma (HTLVI)-infected line, 
HUT  102B2,  for human PHA-activated lymphoblasts, and for the murine, IL- 
2-dependent  CTLL-2  line  was estimated to  be  15-30  nM,  or  ~5,000  times 
higher than that of the saturable binding at picomolar IL-2 levels. Furthermore, 
the number of such low-affinity binding sites was at least 5-10 times the number 
of high-affinity sites. Addition of 10 #M unlabeled IL-2 reduced the binding of 
[3H]IL-2 by 90% or more for each of the concentrations tested (Fig.  2). Thus, 
the low-affinity binding consisted predominately of a saturable component. 
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FIGURE 2.  Typical curve for the binding of [~H]leu,lys IL-2 (2.42 ×  105 dpm/pmol) to HUT 
102B2 cells, PHA-activated (72 h) human lymphoblasts, and murine CTLL-2, subclone 15H 
cells over a  100,000-fold range of IL-2  concentration. Nonsaturable binding on the HUT 
102B2 cells was estimated by including 10 #M unlabeled IL-2. ROBB  ET  AL.  1 131 
To  further evaluate the  proportion  of saturable  binding,  serial  dilutions of 
unlabeled IL-2 were added to [3H]leu,lys IL-2 at three different concentrations 
of the radiolabeled probe. The concentrations of radiolabeled IL-2 were chosen 
to examine high-affinity binding, low-affinity binding, and binding intermediate 
between these two extremes. As shown in Fig. 3, using HUT  102B2 and murine 
CTLL-2 cells, addition of increasing amounts of unlabeled IL-2 resulted in up 
to 99% inhibition of the binding of [3H]leu,lys IL-2 at a low concentration of the 
probe. Similarly, unlabeled IL-2 competed for up to 95 and 87% of the binding 
at  intermediate  and  high  levels  of labeled  factor.  Since  nonspecific  binding 
increases linearly with the concentration of labeled probe, it was not unexpected 
that the level of nonsaturable binding remaining after cold competition repre- 
sented a  larger  fraction of the  total binding for the  low-affinity phenomenon 
than it did for the binding at picomolar concentrations of radiolabeled IL-2. The 
results demonstrate, however, that the low-affinity binding predominantly rep- 
resents specific interaction of the factor with a cellular component(s). 
Relationship of  lL-2 Binding to the Tac Antigen.  Previous studies (6, 7) indicated 
that the anti-Tac antibody could completely inhibit the binding of radiolabeled 
IL-2 at picomolar concentrations of the growth factor. To evaluate the affect of 
the  antibody  on  low-affinity  IL-2  binding,  serial  dilutions  of anti-Tac  were 
combined  with different concentrations of the radiolabeled  IL-2 probe.  Anti- 
Tac inhibited >95%  of the [3H]ieu,lys IL-2 binding to HUT  102B2 cells at the 
lowest concentration of IL-2 (high-affinity binding). At progressively higher IL- 
2 levels, a decreasing proportion of the binding was blocked (Fig. 4). Neverthe- 
less,  at  the  highest  IL-2 concentration,  at which >90%  of the binding should 
,oo  o....  __.220_; 
"~\  \~  ~  1.9 x 10-TM 
(~,]..-=  \\  ,.6x,o,,%.  \ 
20  ~.^  ,,,,, 
*  *  *  ,,~l  o  I  i  ~  J  I  i|||||  |  i  |  tl||||  i~t~  i*|l|  j  i  *  Jtll||  |  *  J  i|11||  i  *  i  *4J 
10"  10  ~°  10"*  10  4  10  .7  10  ~  10  .5 
Concentration of Unlabtled tL-2 (M) 
FIGURE 3.  Competitive inhibition of the binding of [3H]leu,lys 1L-2 (3 different concentra- 
tions) by unlabeled IL-2 using HUT 102B2 and murine CTLL-2, subctone 15H cells. [SH  l- 
leu,lys IL-2 at the concentrations indicated in the figure was combined with serial dilutions of 
unlabeled IL-2, followed by addition of the cells. The concentrations of radiolabeled IL-2 
were chosen to give saturation of the high-affinity  binding sites (1.9 × 10  -~° M total concen- 
tration), half-saturation  of the low-affinity  binding sites (1.6 × 10  -8 M total concentration) and 
saturation of the low-affinity  binding sites (1.9 × 10  -7 M total concentration). 
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FIGURE 4.  Inhibition of the specific binding of [SH]leu,lys 1L-2 (3 different concentrations) 
by unlabeled anti-Tac antibody using HUT 102B2 cells. [3H]leu,lys IL-2 at the concentrations 
indicated in the figure was combined with serial dilutions of anti-Tac antibody, followed by 
addition of the cells. Control murine IgG had no effect on the level of bound [SH]IL-2 even 
when present at 10  -5 M. The number of molecules of [3H]IL-2 bound per cell for each of the 
IL-2 concentrations was 4,720  (2.5  x  10  -~° M),  17,010 (1.6 X  10  -a M), and 64,400 (2.2  x 
10  -7 M). The results were first corrected for the levels of nonsaturable binding determined in 
Fig. 3. 
have been  of the  low-affinity type, the antibody still  inhibited  80-90%  of the 
specific IL-2 binding.  Thus, at least the majority of the low-affinity interaction 
of IL-2 with the HUT  102B2 cells appeared to involve the Tac protein.  At the 
lowest concentration  of [3H]IL-2, where the binding  was entirely  of the high- 
affinity type, a 55-fold molar excess of antibody over growth factor was required 
to reduce the receptor-association by half. In contrast, at the highest concentra- 
tion of [SH]IL-2, where most of the binding was low-affinity, the molar ratio of 
antibody  to  IL-2  at  50%  inhibition  was  1:130.  Thus,  anti-Tac  was  far  more 
efficient in blocking the low-affinity phenomenon. 
In a second approach to evaluating the relationship of IL-2 binding to the Tac 
protein,  serial  dilutions  of  unlabeled  IL-2  were  tested  for  their  efficacy  in 
blocking  the  cellular  binding  of [SH]anti-Tac.  The  concentration  of antibody 
used was sufficient for saturation of the anti-Tac binding sites. Furthermore, the 
number  of antibody-binding  sites  detected in  the  controls exceeded by many 
fold the  number  of high-affinity  IL-2  binding  sites  (see Table  I).  The  results 
demonstrated  that  IL-2  could totally block the  binding  of labeled antibody to 
either  HUT  102B2 or  1C9 cells (Fig.  5).  Thus,  all  the Tac  proteins on  these 
cells appeared capable of interacting with IL-2. At the concentration of antibody 
chosen, a  100-fold molar excess of IL-2 over anti-Tac  was necessary to cause a 
50% reduction in antibody binding. Half-maximal inhibition of anti-Tac binding 
occurred at the same IL-2 concentration  for both cell lines.  Interestingly,  ~8% 
of the anti-Tac binding on the HUT I02B2 cells was inhibited at very low IL-2 ROBB  ET  AL. 
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FIGURE 5.  Inhibition  of the binding of [SH]anti-Tac antibody (1.8 x 10  -9 M total concentra- 
tion) by serial dilutions of unlabeled IL-2 using HUT 102B2 and 1C9 cells. The radiolabeled 
antibody and IL-2 were combined before addition of the cells. The level of radiolabeled 
antibody was chosen to give saturation of the anti-Tac binding sites. 
levels. This amount is very similar to the fraction of high-affinity  IL-2 binding 
sites present on this cell line (Table I). 
Scatchard Analysis  of High and Low Affinity IL-2 Binding and of Anti-Tac Bind- 
ing.  To evaluate the  interaction  of IL-2  with a  variety of cell types, binding 
assays .were separately performed at high and low ranges of IL-2 concentration. 
The  results (Figs.  6-8,  Table  I) indicated  that  at  IL-2 concentrations  below  1 
nM, saturable binding occurred to a  variety of cell types that were positive for 
the IL-2  receptor as defined by monoclonal antibodies (6,  20).  In addition,  as 
was evident at  IL-2  concentrations  above  1 nM,  each  of these  cell  types also 
displayed many-fold higher levels of low-affinity IL-2 binding sites. In contrast, 
unstimulated cells (PBL) and a number of Tac-negative T  cell lines, such as Molt 
3 andJURKAT, and B cell lines, such as Raji and Daudi, lacked the capacity for 
significant high and low affinity IL-2 binding (Table I). The level of IL-2 binding 
on the receptor-positive cells was only slightly increased by elution of endogenous 
factor with a low pH buffer (19). Thus, following preparation of the cells for the 
assay, 90% or more of the high and low affinity binding sites remaining on the 
cell surface appeared unoccupied (data not shown). 
PHA-activated lymphoblasts cultured in IL-2-containing medium for 10 d lost 
most of their high  and low affinity receptors (Table I).  Restimulation  of these 
cells with  PHA resulted in a  dramatic  reexpression of IL-2 binding capacity in 
parallel  with an increase in their  level of the Tac antigen.  The  1C9 B cell line 
displayed both  high  and  low affinity IL-2  binding  sites,  but the  levels of both 
were far below those seen on activated T  cells and the HUT  102B2 line (Table 
I).  PMA-stimulated  HSB2 cells and  a  sample  of B  cells of hairy cell  leukemia 
origin, although positive for anti-Tac binding, displayed few, if any, high-affinity 1134  LOW  AND  HIGH  AFFINITY  IL-2  RECEPTORS 
7,000. 
5,000" 
g 
c~ 
3,000. 
1,000" 
A  ,  HUT 102 
a  a  .....  A PHA-BL 
...........  •  CTLL  o 2 
.... O1C9 
n 
m/,ir.....  ~  ....  ,B ....  •  ..............................  B,, ...................... 
ii 
i'  o  o  @ 
po 
n  i  ,  I  ...... ,  .... I  ,  I 
200  400  600  800 
Free IL-2 (pM) 
-  B  .  •  l  HUT 102 . 
\  .....  •  PHA-BL -- 
1,200  ~  ...........  •  CTLL- 2 
A  -  ~.  ....  OlC9  - 
~o.  1,000 
_~ 
~"  800.  "\~\  ~  - 
\  "  ~  - 
400  '*\'4~  -- 
®  "  \~,,  •  ~e  - 
2o0  .L a . ..~ . ,w  ).\..  N~ 
O" 0"'0  I0- -'r~- .¢11  l~lll ~II'u'i  %  I  l  i~  I 
1,000  3,000  5,000  7,000 
Bound  11--2 (molecules/cell) 
FZGtJ~E 6.  (A) Typical curves for the binding of [SH]leu,lys  IL-2 (3.82  x  105 dpm/pmol) at 
low IL-2  concentrations (i.e.,  high-affinity binding)  to HUT  102B2,  PHA-activated (72  h) 
human lymphoblasts,  1C9 and murine CTLL  2, subclone  15H cells.  Nonsaturable binding 
was estimated by including  10 ttM unlabeled IL-2 in selected tubes. The residual radiolabel 
associated with the cells was subtracted from the total bound fraction found in the absence of 
unlabeled factor to give specific binding. (B) A Scatchard plot of the data in A. 
IL-2  binding  sites  (Table  I).  Almost  all  the  sites  on  these  cells  were  of the  low- 
affinity  variety.  The  ratios  of total  IL-2  binding  sites  for  the  three  murine  cell 
lines  (Table  I) were  approximately  the  same  as the ratios  of mean  fluorescence 
intensity  determined  with  rat  monoclonal  antibody  7D4  (20),  which  is  specific 
for the murine  IL-2  receptor  (data not shown).  The  demonstration  of high levels 
of low-affinity  IL-2  binding  on these  cell  lines  is consistent  with  the intensity  of 
their fluorescence  staining. 
Scatchard  analysis  of  the  assay  results  at  low  IL-2  concentrations  (Fig.  6B) 
produced  straight  lines,  indicating  that  the  binding  for each  cell  type  over  this ROBB  ET  AL.  1135 
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lymphoblasts. The results were corrected for nonsaturable binding by measuring the residual 
binding in the presence of 10 uM unlabeled IL-2. (B) A Scatchard plot of the data in A (solid 
lines). The contribution of high-affinity binding sites was subtracted from the values of total 
bound factor to reveal the approximate characteristics of the low-affinity binding  phenomenon 
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range  of  IL-2  levels  was  characterized  by  a  single  affinity.  The  enormous 
difference in the dissociation constants for the high and low affinity phenomena, 
which was emphasized by the binding curves depicted in Fig. 2, explains why the 
low-affinity binding  has  no detectable effect on the association curves at these 
IL-2 concentrations.  The apparent  dissociation constant, averaged over several 
experiments,  was -4  pM  for the human  PHA-lymphoblasts and  HUT  102B2 T
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 1138  LOW  AND  HIGH AFFINITY 1L-2 RECEPTORS 
cells (Table I). This value is in  good agreement  with that previously measured 
(3), particularly  when corrections (16) are made in the specific radioactivity of 
the probe used in the former study. The  1C9 B cell line initially demonstrated 
an affinity for IL-2 at low factor concentrations that was fivefold lower than that 
of the  human  T  cells (Table  I).  After  2  mo  in  culture,  however,  its  level  of 
receptors  and  the  apparent affinity  both  declined.  Freshly  thawed  cultures 
underwent the same apparent decline in affinity. The high-affinity factor binding 
sites on the murine CTLL-2 line had a dissociation constant comparable to that 
previously measured (3).  In contrast, the CTL and HT-2 lines appeared to have 
threefold lower affinities for IL-2 for this range of factor concentrations (Table 
I). 
Scatchard analysis of the assay results at high IL-2 concentrations using PHA- 
lymphoblasts and HUT  102B2 cells (Fig. 7) demonstrated that the data formed 
curvilinear  plots  indicative  either  of a  mixture  of binding  sites  with  different 
affinities or of negative cooperativity. It should be noted that  the results were 
first corrected for nonspecific, nonsaturable  binding before they were plotted. 
If the contribution of the high-affinity sites of each cell type was first subtracted, 
the plots usually approximated  straight  lines (Fig.  7B). The Ka for the various 
types of human  cells was roughly  30 nM,  indicating that  this class of receptors 
had an affinity over 5,000 times lower than that of the high-affinity IL-2 binding 
sites.  A  similar  dissociation  constant  was found for the  three  IL-2-dependent 
murine T  cell lines (Fig. 8, Table I). The CTL and HT-2 lines expressed a much 
higher  density of low-affinity binding  sites on their  surface than  the  CTLL-2 
cells. For both these lines, the high-affinity sites represented a minor fraction of 
the total binding. As a consequence, the Scatchard plots at high IL-2 concentra- 
tions were nearly linear (Fig.  8B), even without correction for the high-affinity 
binding component. 
Using  [3H]anti-Tac,  the  number  and  affinity of antibody-binding  sites  were 
estimated for each of the human cell types. As shown in Fig. 9 for a representative 
experiment, saturable binding of the antibody occurred on both PHA-lympho- 
blasts and  HUT  102B2 cells and  the Scatchard analysis demonstrated  a  single 
class of binding  sites.  Preliminary  results  with  Fab fragments  of anti-Tac  sug- 
gested that the binding of the intact antibody, as measured  under these condi- 
tions,  was monovalent (J.  M.  Depper and  W.  C.  Greene,  unpublished observa- 
tion). Thus, assuming only a one-to-one ratio of bound antibody to Tac protein, 
the average number of Tac proteins on the various human cell types was found 
to be reasonably close (usually within  a  factor of 2) to the average number  of 
total IL-2 binding sites (Table I).  This result suggests that each 55,000  mol wt 
Tac molecule is capable of binding one molecule of IL-2. The total number of 
factor binding  sites was somewhat lower than  the number of anti-Tac  binding 
sites  in  the  case  of the  PHA-lymphoblasts  and  HUT  102B2  cells.  For  the 
stimulated  HSB2 cells and  the two Tac-positive B  cell samples,  the number  of 
IL-2 binding sites equaled or slightly exceeded (1C9 cells) the number of sites 
detected with radiolabeled antibody (Table I). 
The  apparent  affinity  of anti-Tac  binding  was ~40-fold  lower than  that  of 
high-affinity  IL-2 binding  to the HUT  102B2 cells but ~200-fold higher  than 
that of the low-affinity IL-2 phenomenon (Table I). These values are quite similar ROBB  ET  AL.  1139 
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was estimated by including 1 #M unlabeled anti-Tac antibody in selected tubes. The residual 
radiolabel associated with the cells was subtracted from the total bound fraction found in the 
absence of unlabeled antibody to give specific binding. (B) A Scatchard plot of the data in A. 
to the ratios obtained from competition binding analysis. It took a 55-fold molar 
excess of anti-Tac to reduce high-affinity IL-2 binding on HUT  102B2 cells by 
half,  but  only  a  1:130  ratio  of antibody  to  IL-2  to  block  low-affinity  factor 
binding by an equal amount (Fig. 4). Similarly, in the reverse experiment, it took 
a  100-fold  molar  excess of IL-2  to  block the  binding  of [3H]anti-Tac  to  the 1140  LOW  AND  HIGH  AFFINITY  IL-2  RECEPTORS 
predominant low-affinity receptors by  50%,  but  only a  1:60  ratio of IL-2  to 
antibody to block the binding of anti-Tac to the small fraction of high-affinity 
IL-2 binding sites (HUT 102B2 cells, Fig. 5). 
Discussion 
The original radiolabeled IL-2 binding studies of Robb et al. (3) demonstrated 
that the growth factor interacted with activated T  cells with a particularly high 
affinity. This and subsequent investigations (4, 19) provided substantial evidence 
that  the high-affinity interaction directly correlated with the physiological re- 
sponse of these cells to  IL-2.  In  separate studies,  the cellular site for growth 
factor binding was shown to be associated with the protein recognized by the 
anti-Tac  monoclonal antibody (6-8).  Nevertheless, discrepancies between the 
IL-2 and anti-Tac binding assays raised questions as to whether the factor and 
antibody-reactive sites were due to  coincident, or merely overlapping,  sets of 
molecules (10). For the particular cell types studied here, three lines of evidence 
argue that  the sets are,  in  fact, coincident.  First,  inclusion of the low-affinity 
phenomenon in  the total  for IL-2  binding greatly reduced the numerical dis- 
crepancy between the IL-2 and anti-Tac binding assays (Table I). The relatively 
minor quantitative difference remaining could certainly be due to inherent errors 
in estimation of the specific radioactivity of one or both probes. The radiolabeled 
IL-2 preparation, for example, required an indirect approach for estimation of 
its protein content (see Materials and Methods). In addition, potential endoge- 
nous production of IL-2 or other growth-promoting substances (21) may have 
competed for some of the radiolabeled factor binding in the case of the PHA- 
lymphoblasts and HUT 102B2 cells. The level of low-affinity IL-2 binding may 
also have been underestimated due to overcompensation for nonspecific inter- 
action of IL-2 with the cells. Second, inclusion of unlabeled anti-Tac antibody 
substantially  inhibited  binding  of radiolabeled  IL-2  over the  entire range  of 
IL-2 concentrations (Fig. 4), indicating that the low-affinity, as well as the high- 
affinity, binding was probably attributable to the Tac protein. Thus, in the case 
of the HUT 102B2 cells, the low-affinity interaction, in addition to being largely 
saturable  (Fig.  3),  was  not  due  to  cross-reaction  with  an  unrelated  surface 
receptor. Finally, excess IL-2 totally blocked radiolabeled anti-Tac binding (Fig. 
5),  implying that all Tac proteins were capable of recognizing IL-2 with some 
affinity. The detection of a large pool of low-affinity factor binding sites on the 
murine cell lines suggests that a multiplicity of binding affinities explains a similar 
quantitative discrepancy with the anti-receptor antibody studies in that species. 
The near equivalence of the binding site numbers obtained in the IL-2 and 
anti-Tac assays for PHA-lymphoblasts is consistent with the finding for this cell 
type  that  anti-Tac  and  IL-2-coupled  affinity supports  were  each  capable  of 
removing all  the  cellular  proteins  reactive  with  the  alternative  support  (7). 
Furthermore, the relationship between the affinities of the two types of IL-2 
binding sites and that of the anti-Tac antibody provides a potential explanation 
for the seemingly contradictory finding that a large molar excess of each ligand 
was necessary to block the binding of the other ligand (Figs.  4 and 5; references 
7 and 9).  Based on the ratios of affinities, a molar excess of antibody would be 
necessary to block high-affinity  IL-2  binding with its 40-fold lower dissociation ROBB  ET  AL.  1141 
constant. On the other hand, a molar excess of IL-2 would be necessary to block 
binding of anti-Tac to the more prevalent low-affinity  IL-2  sites, since for this 
class of receptors the antibody has the higher affinity. This simple model assumes 
that the antibody and IL-2 interact with the Tac protein at overlapping sites and 
that the inhibition  of binding arises  from steric hindrance.  More complicated 
models would have to be invoked if the two ligands bind at distant sites on the 
Tac  molecule  and  block  each  other's  binding  by  inducing  conformationa] 
changes. 
To a  first approximation,  the  IL-2  binding appeared  to be composed of a 
single high-affinity and a single low-affinity component (Fig. 7B). It was difficult, 
however, to distinguish between the existence of two distinct binding phenomena 
and a mixture of sites with a continuous range of affinities. Moreover, negative 
cooperativity between receptor molecules could account for some of the apparent 
differences in affinity and the curvature of the low-affinity Scatchard plots (22). 
The variability seen within a  species in the dissociation constant for the high- 
affinity binding phenomenon (i.e., early and late IC9 cultures and the three IL- 
2-dependent murine lines) was unexpected considering the consistency seen in 
a previous survey of receptor-positive cells (23).  Since equilibrium binding can 
be affected by such things as ligand-receptor internalization and ligand degra- 
dation, however, conclusions about the variable nature of the IL-2 binding must 
await  additional  approaches,  including  kinetic  analysis  of ligand  binding  on 
isolated  cell  membranes and  molecular analysis of the different states  of the 
receptor molecule. The apparent dissociation constants listed in Table I result 
from the use of a  certain methodology and set of conditions and arise from a 
simplistic mathematical derivation (Fig. 7 B). Although these values may thus be 
biased, any errors will have a negligible effect upon the enormous difference in 
Kd's measured for the high and low affinity classes of IL-2 receptors and thus 
will not alter the central argument that IL-2 can interact with certain cells with 
more than a single affinity. 
The  Tac  protein  was  recently purified  to  homogeneity by  immunoaffinity 
chromatography (24). Amino-terminal sequence analysis indicated the presence 
of a single polypeptide chain. Using a synthetic oligonucleotide probe based on 
the sequence information, cDNAs corresponding to the IL-2 receptor mRNA 
were isolated and sequenced. Expression of one of these cDNA clones in Cos-1 
cells resulted in  display of molecules on the cell surface that were capable of 
binding radiolabeled IL-2 and anti-Tac (24).  Moreover, examination of several 
cell types using the cDNA clone suggested that a  single structural gene coded 
for this component of the IL-2 receptor (24). Thus, molecular heterogeneity of 
the Tac protein (25) is probably generated by differences in posttranslational 
modifications, which include sulfation, disulfide bonding, phosphorylation, and 
extensive glycosylation.  2 Such differences could account for the disparity between 
low  and  high  affinity  IL-2  binding.  Although  each  of the  precursors  in  the 
maturation of the Tac protein was capable of binding to an IL-2-coupled affinity 
Leonard, W. J., J. M. Depper, M. Kr6nke, R.J. Robb, T. A. Waldmann, and W. C. Greene. The 
human receptor for T-cell growth factor (TCGF): evidence for sulfation, phosphorylation, variable 
post-translational processing, and the ability of precursor  forms of the  receptor  to bind TCGF. 
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support, 2 it was not possible from that analysis to determine whether their affinity 
for IL-2 varied. 
The  finding of IL-2  binding  sites with  multiple  affinities  is not unexpected, 
given the results obtained with other polypeptide growth factors. The receptor 
for nerve growth factor was shown to exist in two states which differed in affinity 
17-fold (26, 27). These forms could be interconverted by interaction with wheat 
germ agglutinin,  indicating  that the affinity differences were due to conforma- 
tional changes (26, 28). Similarly, the receptor for epidermal growth factor was 
found to exist in low and high affinity states (29), which could be interconverted 
by binding of a monoclonal anti-receptor antibody (30). As with IL-2 and T  cell 
proliferation, the less numerous high-affinity sites appeared to be responsible for 
the growth-promoting properties of epidermal growth factor on one particular 
cell line (29).  Finally, cellular receptors for platelet-derived growth factor were 
also shown to express two distinctly different affinities, depending upon condi- 
tions  of temperature  and  ligand  binding  (31).  Thus,  in  addition  to  potential 
differences  in  posttranslational  modification,  the  variation  in  IL-2  receptor 
affinity could be due to conformational changes caused by interaction of the Tac 
protein with a different hypothetical receptor subunit (10) or by dimerization  of 
the  Tac  molecule,  as  was  postulated  in  the  case  of the  nerve  growth  factor 
receptor (28).  Alternatively, separate high and low affinity binding sites for IL- 
2 could be present on the same molecule. 
The low-affinity IL-2 binding sites were found on all Tac-positive cells tested 
but not on several Tac-negative lines (Table I). The presence of both high and 
low affinity IL-2 receptors on the  1C9 B cell line and the B cells obtained from 
the  HCi sample  was  unusual  but not  without  precedence (32).  Selected EBV- 
transformed  B  cell  lines,  mitogen-activated  normal  B  cells,  and  B  cells  from 
patients with hairy cell leukemia (HCL) were all shown to display the Tac protein 
(32, 33). In fact, one such B cell line was shown to respond to low concentrations 
of homogeneous  IL-2  with  increased  immunoglobulin  secretion  (32).  As  ex- 
pected, this response was blocked by the anti-Tac antibody. The excess of IL-2 
binding sites over antibody binding sites on the 1  C9 cell line, however, raises the 
possibility that  a  fraction  of the  low-affinity sites  on this  particular  line  might 
represent cross-reaction with a surface component which is unrelated to the Tac 
protein. 
The  proportion  of high  and  low affinity binding  sites for  the  different  cell 
types varied (Table I). For example, most of the initial increase in Tac expression 
upon  restimulation  of 9-d-old  PHA-lymphoblasts corresponded  to  low-affinity 
sites.  The  same was found  for PMA-induced  receptors on  HSB2 cells and  the 
receptors displayed on the B cells in the HCL sample.  In addition,  the ratio of 
low to high affinity binding for the murine CTL and HT-2 lines was higher than 
that  for the CTLL-2 line.  Thus,  display of the protein recognized by the anti- 
Tac or 7D4 antibodies was not always a quantitative  measure of the capacity of 
the  cells  for  high  affinity  interaction  with  IL-2.  Analysis  of  IL-2  receptor 
expression should therefore include a  determination  of the relative prevalence 
of high and low affinity IL-2 binding sites. 
The  low-affinity binding  sites for IL-2 are  unlikely to directly participate  in 
normal physiological responses to the factor, since at concentrations that might ROBB  ET  AL.  1143 
occur in vivo (<200 pM)  3 only a  minute fraction (<1%) of such sites would be 
occupied. In contrast, the same concentration would saturate the high-affinity 
sites. Nevertheless, a high enough local concentration of IL-2 might momentarily 
exist if the producing and responding cells are in contact or if the secreting cell 
also displays low-affinity receptors. Moreover, the low-affinity sites may act as a 
pool  of components for generation of high-affinity receptors.  If ways can be 
found to interconvert high and low affinity IL-2 binding sites, as was done for 
the nerve growth factor receptor (26), it may be possible to conclusively deter- 
mine the contribution of each form of the molecule to any particular physiological 
response.  In the meantime, there is ample reason to exercise caution in inter- 
preting the results of experiments employing high concentrations of IL-2.  In 
each case, the factor concentration necessary for the cellular response should be 
compared with  the dissociation constant(s) and density of the  IL-2  receptors. 
Both of the latter factors will be crucial in determining the extent of the response 
(4).  If the  analysis  indicates  that  few,  if any,  receptors  are  present  with  an 
appropriate affinity, then alternative explanations, such as contaminants in the 
IL-2 preparation, should be explored. Similarly, putative responses to IL-2 by 
cells that are negative for the Tac protein may represent the effects of contami- 
nants in the IL-2 preparation or an indirect effect upon residual T  cells in the 
cell population (34).  In addition, they might be due to cross-reaction of IL-2 at 
very high concentrations with receptors for distinct growth or differentiation 
factors.  In  fact,  the  latter  possibility  has  been  invoked to  explain  the  IL-2- 
dependent induction of immunoglobulin secretion for a Tac-negative B cell line, 
SKW6.4  (35).  Clearly, attribution  of physiological effects to  the kind of low- 
affinity IL-2 receptor described here requires the elimination of several compet- 
ing explanations. 
Summary 
Interleukin 2 promotes proliferation of T  cells by virtue of its interaction with 
a high-affinity cell surface receptor. This receptor is a 55,000 mol wt glycoprotein 
that is also recognized by the murine monoclonal antibody, anti-Tac. Quantitative 
binding studies with radiolabeled IL-2 and anti-Tac, however, initially indicated 
far more antibody binding sites per cell than IL-2 binding sites. Extension of the 
IL-2 binding analysis to concentrations several thousand-fold higher than that 
necessary for the T  cell proliferative response demonstrated the existence of a 
class  (or classes)  of low-affinity IL-2 binding sites.  Inclusion of the low-affinity 
IL-2 binding greatly reduced the quantitative discrepancy in the ligand binding 
assays. That the low-affinity binding, as well as the high-affinity interaction, was 
associated with the Tac molecule was indicated by the finding that the antibody 
could substantially or totally block the entire spectrum of IL-2 binding and by 
the finding that IL-2 could in turn block all radiolabeled anti-Tac binding. The 
low-affinity sites were found on activated T  cells, several human and murine T 
cell lines and two examples of Tac-positive B cells. The physiological role of the 
low-affinity IL-2 binding sites and the molecular changes in the Tac protein that 
give rise to the affinity differences remain open to investigation. 
3 Equivalent to the typical concentration of IL-2 released in vitro after 24 h  by  1 x  106 PBL/m] 
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